Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Low-Fat Diet and Skin Cancer Risk: The Women's Health Initiative Randomized Controlled Dietary Modification Trial

Christina S. Gamba, Marcia L. Stefanick, James M. Shikany, Joseph Larson, Eleni Linos, Stacy T. Sims, James Marshall, Linda Van Horn, Nathalie Zeitouni and Jean Y. Tang
Christina S. Gamba
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcia L. Stefanick
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James M. Shikany
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Larson
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleni Linos
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stacy T. Sims
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Marshall
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Van Horn
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Zeitouni
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Y. Tang
1Stanford School of Medicine; 2Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford; 3University of California San Francisco School of Medicine, University of California San Francisco, San Francisco, California; 4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; 5WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington; 6Department of Dermatology, Roswell Park Cancer Institute and University of Buffalo, Buffalo, New York; and 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-13-0341 Published September 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Large cohort studies have reported no relationship between dietary fat and nonmelanoma skin cancer (NMSC), although a low-fat diet intervention reduced NMSC risk in a small clinical trial. In animal studies, skin tumor development has been reduced by low-fat diet. We evaluated the effect of a low-fat dietary pattern on NMSC and melanoma in the Women's Health Initiative Dietary Modification trial.

Methods: Postmenopausal women aged 50 to 79 years (n = 48,835) were randomly assigned to the low-fat dietary pattern intervention (n = 19,541) or comparison group (n = 29,294). The intervention goals included decreasing fat intake to 20% or less of calories, increasing vegetable and fruit intake, and increasing grain intake. Self-reported incident NMSC (n = 4,907) and physician-adjudicated incident melanoma (n = 279) were ascertained every 6 months.

Results: Over 8.1 years of follow-up, the low-fat diet intervention did not affect overall incidence of NMSC [HR 0.98; 95% confidence interval (CI), 0.92–1.04] or melanoma (HR, 1.04; 95% CI, 0.82–1.32). In subgroup analyses of melanoma risk, baseline fat intake interacted significantly with group assignment (Pinteraction = 0.006). Among women with higher baseline fat intake, the dietary intervention significantly increased risk (HR, 1.48; 95% CI, 1.06–2.07), whereas, among women with lower baseline fat intake, the intervention tended to reduce melanoma risk (HR, 0.72; 95% CI, 0.50–1.02).

Conclusions: In this large randomized trial, a low-fat dietary pattern did not affect overall incidence of NMSC or melanoma.

Impact: A low-fat diet does not reduce incidence of NMSC, but an interaction between baseline fat intake and dietary intervention on melanoma risk warrants further investigation. Cancer Epidemiol Biomarkers Prev; 22(9); 1509–19. ©2013 AACR.

Introduction

Skin cancer is the most common malignancy in the United States, affecting more than 2 million individuals in 2006, which is double the incidence reported in 1994 (1, 2). The American Cancer Society estimated that Americans would develop 3.5 million new cases of nonmelanoma skin cancer (i.e., basal cell and squamous cell carcinomas) and 76,250 new cases of melanoma in 2012 (1, 3). Sun exposure is the main established risk factor for skin cancer; however, only part of the variation in skin cancer incidence is explained by variables related to sun exposure (4–7). Despite public health campaigns emphasizing sunscreen use and sun avoidance, incidences of nonmelanoma skin cancer (NMSC) and melanoma continue to rise, especially among women (8–10). Consequently, there is a great need to identify other modifiable risk factors for skin cancer and new approaches for skin cancer prevention.

Clinical studies of dietary fat and NMSC are inconsistent (11–18). One large prospective cohort found no relationship between dietary fat intake and NMSC risk in women, while another noted lower NMSC risk with higher dietary fat intake in men (16, 18). On the other hand, a 2-year randomized trial of subjects with a history of NMSC reported that a low-fat diet intervention reduced NMSCs in the last 8 months of the study, but not in the first 16 months (11, 20). The clinical data on dietary fat and melanoma are also inconsistent (19–24).

There is a biologic rationale for an association between fat intake and risk of skin cancer. Laboratory studies have shown that a high-fat diet contributes to oxidative stress and DNA damage (25), increasing inflammatory cytokines in the skin while decreasing cell apoptosis (26). One study found a nearly linear relationship between increasing lipid level and development of actinic tumors in mice, noting both shorter time to tumor formation and greater number of tumors (27). Another study noted that low-fat diet was associated with slower melanoma tumor growth (28).

The Women's Health Initiative (WHI) Dietary Modification (DM) Trial of 48,835 postmenopausal women, designed to evaluate whether a low-fat dietary pattern intervention would decrease the incidence of breast and colorectal cancers (primary outcomes) and/or coronary heart disease (secondary outcome; ref. 29–32), provides an opportunity to investigate whether a low-fat dietary pattern reduces the risk of NMSC or melanoma within a large randomized controlled trial.

Materials and Methods

Study population

The WHI DM Trial (NCT00000611) design has been described previously, as have eligibility criteria and recruitment methods (29, 33, 34). Briefly, postmenopausal women, aged 50 to 79 years, were recruited at 40 Clinical Centers throughout the United States between 1993 and 1998. Major exclusions included previous history of breast, colorectal, or any cancer other than nonmelanoma skin cancer in the past 10 years; predicted survival of less than 3 years; type I diabetes mellitus; and other conditions that posed adherence and retention concerns (e.g., alcoholism, dementia; ref. 33). Participants had to have a baseline fat intake 32% or more of total energy, as estimated by the WHI Food Frequency Questionnaire (FFQ).

Study design

Eligible women (n = 48,835) were randomly assigned by permuted block algorithm to either the dietary intervention (40%, n = 19,541) or the comparison group (60%, n = 29,294). The dietary goals for the intervention group included decreasing total fat intake to 20% or less of energy and consuming 5 or more servings per day of vegetables and fruits and 6 or more servings per day of grains. The women received an individualized dietary plan with a daily fat gram goal based on their expected energy intake (29). The intervention did not include weight loss or total energy reduction goals. Women in the intervention group participated in nutritionist-facilitated small group sessions (18 sessions during year 1 and quarterly sessions each year thereafter). Women assigned to the comparison group received a copy of Nutrition and Your Health: Dietary Guidelines for Americans but were not asked to change their diet (30, 35). The trial design for comparison–intervention difference in percentage of energy from total fat was 13% at year 1 and 11.75% at year 6. Among all participants, the actual comparison–intervention difference at year 1 and year 6 was 10.7% and 8.1%, respectively (30).

Demographic information, medical history, and other characteristics were obtained by questionnaire or physical measurement at study entry (baseline). This analysis included all women enrolled in the DM Trial, except participants with missing data for body mass index (BMI) at baseline. All procedures and protocols were approved by the Institutional Review Boards at each participating institution and all participants provided written informed consent.

Follow-up and data collection

On average, women in the DM Trial were followed for 8.1 years (SD, 1.6 years). As of March 2005, the percentage of women still actively participating in the trial was similar between the 2 groups, with 17,674 women in the dietary intervention group (90.4%) and 26,677 in the comparison group (91.1%; ref. 30). Clinical measures (such as weight) and self-reported measures (such as physical activity) of the participants were collected during annual clinic visits (29).

The WHI FFQ was used to assess dietary intake in both groups. All participants completed the FFQ at baseline (before randomization) and year 1. After year 1, a rotating sample of 33% of participants was surveyed each year, such that each participant completed a FFQ every 3 years. A detailed description of the FFQ validation has been published (36). The response rate to the FFQ was 100% at baseline and approximately 81% in subsequent years (32). The nutrient database was derived from the University of Minnesota Nutrition Coordinating Center nutrient database (NDSR, Minneapolis, Minnesota; ref. 36).

Outcome ascertainment

Participants completed questionnaires every 6 months to report medical outcomes, including NMSC and melanoma (37). Melanoma cases were confirmed by adjudication of pathology reports, and coded as invasive or in situ following the ICD-O-2 coding scheme (38). NMSC cases were not adjudicated.

Statistical analysis

Baseline descriptive characteristics, potential skin cancer risk factors, and dietary intake were compared in the intervention and comparison groups. Differences in each category were evaluated using χ2 tests for categorical variables and t tests for continuous variables.

In post hoc analyses, incidence of NMSC and melanoma were compared between the groups using HRs with 95% confidence intervals (CI) and Wald statistic P values from Cox proportional hazards models. The proportionality assumption was confirmed by running a proportional hazards model that modeled each outcome as a function of the interaction between the low-fat dietary pattern effect and the log survival time. Modeling analyses used time-to-event methods according to the intention-to-treat principle. Kaplan–Meier estimates were provided to describe event rates over time. As in prior analyses of the DM Trial (30), sensitivity analyses were conducted by censoring intervention participants who missed an annual clinic visit, failed to participate in 9 or more of the 18 first year group sessions, or failed to participate in 2 or more of the 4 group sessions in subsequent years; or comparison participants who missed an annual clinic visit. With these criteria, the adherence rates in the intervention group were 57% at year 3, 31% at year 6, and 19% at year 9, whereas the adherence rates in the comparison group were 87%, 75%, and 65% (30). All proportional hazards models were stratified by age groups at recruitment (50–54, 55–59, 60–69, and 70–79) and randomized treatment assignment in the other WHI clinical trials (34), that is, the Hormone Therapy Trials of combined estrogen and progestin (39) or estrogen only (40) and the Calcium/Vitamin D Trial (41).

To assess whether the effect of low-fat dietary pattern on NMSC or melanoma risk varied according to baseline risk factors for both types of skin cancer, Cox proportional hazards models were extended to include the variable of interest and interaction with group assignment. HRs for intervention versus comparison within each subgroup are presented along with the Pinteraction. Twelve predefined subgroup analyses were conducted for NMSC and melanoma to assess possible statistical interactions between a low-fat dietary pattern and the following known or potential skin cancer risk factors at baseline: (i) age, (ii) BMI, (iii) regional solar radiation, (iv) history of NMSC, (v) smoking status, (vi) use of nonsteroidal anti-inflammatory drug (NSAID), (vii) vitamin D intake, (viii) total energy intake, (ix) percentage of energy from total fat intake, (x) total fat intake, (xi) vegetable and fruit servings, and (xii) grain servings. Cut-off points for age, BMI, and regional solar radiation were previously defined in the WHI clinical trials. For NMSC, baseline dietary intake was evaluated by quartiles determined by the natural distribution of participants' intake at baseline. For melanoma, as there were fewer cases, baseline dietary intake is presented by 2 methods: the intake groups for energy and fat are divided into an top and bottom half determined by the mean intake of the cohort, whereas the intake groups for vegetable and fruit servings and grain servings are presented by the upper quartile versus the lower three quartiles to reflect current intake recommendations for cancer prevention (42, 43). All statistical analyses were completed using SAS 9.2 (SAS Institute Inc). All statistical tests were two-sided.

Results

Baseline characteristics of participants

Table 1 shows baseline characteristics of participants in the dietary intervention and comparison groups. Participants had an average age of 62.3 years (SD, 6.9 years) and an average BMI of 29.1 kg/m2 (SD, 5.9 kg/m2). The demographics, health behaviors, skin cancer risk factors [i.e., sun exposure (measured via regional solar radiation and total outdoor walking) and history of NMSC and melanoma), and medical history were comparable between the randomization groups.

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics of participantsa

Nonmelanoma skin cancer

Incidence of self-reported NMSC was similar between randomization groups over an average follow-up of 8.1 years, with 1,923 NMSC cases in the dietary intervention group and 2,984 cases in the comparison group (annualized percentage of 1.28% vs. 1.32%; HR, 0.98; 95% CI, 0.92–1.04; Table 2; Fig. 1). Even when participants with a history of NMSC were excluded, NMSC incidence did not differ between the groups (HR, 0.97; 95% CI, 0.91–1.04), nor did NMSC outcomes differ by group assignment within any of the predefined subgroups [i.e., age, BMI, regional solar radiation (langleys), history of NMSC, smoking, NSAID use, vitamin D intake, total energy or fat intake, or vegetable and fruit servings; Table 4].

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Kaplan–Meier estimate of cumulative hazards for nonmelanoma skin cancer events (n = 4,907). Cox proportional hazards, Wald statistic Pinteraction.

View this table:
  • View inline
  • View popup
Table 2.

Number of nonmelanoma skin cancer and melanoma events by overall trial and sensitivity analysis

Melanoma

Incidence of physician-adjudicated melanoma was similar between randomization groups, with 114 melanoma cases in the dietary intervention group and 165 cases in the comparison group (annualized percentage of 0.07% vs. 0.07%; HR, 1.04; 95% CI, 0.82–1.32; Table 2; Fig. 2). Melanoma incidence was similar between the groups even when participants with a history of melanoma were excluded (HR, 1.04; 95% CI, 0.82–1.32); however, in subgroup analysis, there was a significant differential effect of low-fat dietary intervention on risk of melanoma by baseline fat intake (Pinteraction = 0.006). Specifically, women with higher baseline fat intake (≥36.9% of total energy, or the upper half of baseline intake as determined by the mean of the participants) had a significantly higher melanoma risk (HR, 1.48; 95% CI, 1.06–2.07), whereas women with lower baseline fat intake (<36.9% of total energy) trended toward lower melanoma risk (HR, 0.72; 95% CI, 0.50–1.02) when assigned to dietary intervention versus comparison (Table 3, Fig. 3). A significant differential effect of the low-fat dietary intervention on melanoma risk was also found by baseline vegetable and fruit intake (Pinteraction = 0.037), with women in the lower 3 quartiles of vegetable and fruit servings per day at baseline (≤ 4.6) trending toward higher risk of melanoma (HR, 1.26; 95% CI, 0.95–1.67), whereas women in the upper quartile tended to have lower melanoma risk (HR, 0.65; 95% CI, 0.41–1.03) when assigned to dietary intervention versus comparison. Dietary intervention did not affect melanoma within any other subgroups.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan–Meier estimate of cumulative hazards for melanoma events (n = 279). Cox proportional hazards, Wald statistic Pinteraction.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Effect of dietary modification on risk of melanoma, according to baseline dietary factors targeted by intervention (n = 279). Cox proportional hazards, Wald statistic Pinteraction. *Models were adjusted for age, assignment in the Hormone Therapy trial, and assignment in the Calcium/Vitamin D trial.

View this table:
  • View inline
  • View popup
Table 3.

Estimated effect of dietary modification on risk of melanoma, according to selected baseline characteristics

View this table:
  • View inline
  • View popup
Table 4.

Estimated effect of dietary modification on risk of nonmelanoma skin cancer (NMSC), according to selected baseline characteristics

Sensitivity analysis

In analyses in which participants who did not fully comply with the trial requirements were censored (e.g., participants from the intervention group who missed an annual clinic visit, failed to participate in ≥ 9 of the 18 first year group sessions, or failed to participate in ≥ 2 of the 4 group sessions in subsequent years; or comparison participants who missed an annual clinic visit; ref. 30), incidences of NMSC and melanoma were similar in the intervention and comparison groups (NMSC: HR, 0.99; 95% CI, 0.92–1.07; melanoma: HR 1.04; 95% CI, 0.75–1.43; Table 2). Limiting the primary analysis to Caucasian women showed similar results, with no significant difference in incidence of NMSC or melanoma. A time-dependent analysis of weight loss did not alter the relationship between diet and skin cancer risk (data not shown).

Discussion

The WHI Dietary Modification Trial is the largest randomized controlled trial to evaluate whether a low-fat dietary pattern, with decreased fat intake and increased vegetable, fruit, and grain intake, reduces cancer risk in postmenopausal women. A low-fat dietary pattern did not affect the overall incidence of nonmelanoma skin cancer or melanoma over an average 8.1-years of follow-up.

Although the comparison–intervention difference in percent of energy from total fat was lower than anticipated, the intervention group maintained a significant long-term difference in the percentage of energy from total fat versus the comparison group (−8.1%, P < 0.001; refs. 30, 44), as well as vegetable and fruit intake (1.1 servings per day, P < 0.001) and grain intake (0.4 servings per day, P < 0.001; refs. 30, 37). Even though these differences were small, this dietary intervention was shown to reduce breast cancer risk significantly among participants in the upper quartile of dietary fat at baseline, thus suggesting that biologically meaningful changes in diet were achieved in the WHI DM Trial (30). Notably, the small but significant decrease in polyunsaturated fat in the WHI intervention versus comparison group (−1.5% at year 6, P < 0.001; ref. 32) was not associated with risk of skin cancers, consistent with several studies of NMSC (11, 12, 16, 18) and melanoma (22–24).

Our overall null results are consistent with several observational studies that found no association between fat intake (16, 17) or vegetable and fruit intake (15, 17, 18) and risk of NMSCs (i.e., basal cell and/or squamous cell carcinomas). A 4-year prospective study of 73,366 women without history of skin cancer in the Nurses' Health Study found no overall association between dietary fat intake and incidence of basal cell carcinoma (16), while an 8-year prospective study of 43,217 men without history of skin cancer in the Health Professionals Follow-up Study found that higher percentage of energy from total fat was associated with lower risk of basal cell carcinoma (18). An 11-year prospective cohort within a randomized trial of beta-carotene and daily sunblock also found no overall association between dietary fat intake and incidences of basal cell and squamous cell carcinoma (12).

In a previous 2-year trial (11) of low-fat diet, the average number of NMSCs among 101 participants with a history of skin cancer was only lower in the last 8 months of the intervention, suggesting that greater follow-up might be required to determine the effect of diet on skin cancer. However, in our 8-year trial we saw no effect of dietary intervention on NMSC among participants with a history of skin cancer. Notably, the trial by Black and colleagues (11) achieved a greater decrease in percentage of energy from total fat than in the DM Trial (30).

Our results are the first to evaluate melanoma risk within a randomized trial of low-fat diet. One prospective cohort (19) and several case–control studies (21–24) showed no association between total fat intake (19, 21–24) or vegetable and fruit intake (24) and melanoma. Other studies found lower risk of melanoma with higher fat intake (20) and vegetable and fruit intake (21). In subgroup analysis, we found a significant, differential effect of low-fat diet on melanoma risk depending on baseline fat intake of participants, and also vegetable and fruit intake. Women with higher baseline fat intake (≥36.9% of total energy) assigned to dietary intervention had a higher risk of melanoma, whereas women with lower baseline fat intake (32 to 36.9%) trended toward lower melanoma risk. A similar differential effect was seen among participants in the intervention group by baseline vegetable and fruit intake. Thus, perhaps women with unhealthier baseline diets (e.g., high fat intake and low vegetable and fruit intake at baseline) assigned to dietary intervention became more health-conscious during the trial, and underwent skin examination leading to increased diagnosis of melanoma. Other studies have shown that healthy habits, such as physical activity and healthy diet, may be associated with cancer screening (45, 46). In contrast, participants in the intervention group with healthier baseline diets (e.g., moderate-fat intake and greater vegetable and fruit intake at baseline) may have achieved an even lower fat diet than their counterparts in the intervention group, leading to a trend toward lower melanoma risk. Further investigations on the effect of greater dietary modification than that achieved in the WHI DM Trial on risk of melanoma may be merited. Notably, these results should be interpreted with caution given the multiple subgroups tested.

The strengths of this study include the randomized dietary intervention, the large diverse study population, and the long follow-up time. This analysis is the first to assess melanoma risk within a randomized controlled trial of low-fat diet. This study has several limitations. The primary limitation is that the intervention group did not achieve the comparison–intervention goal, and the percentage of participants who adhered to the trial requirements decreased as the trial progressed. However, a sensitivity analysis that was restricted to those who complied did not show an effect of low-fat dietary pattern on risk of skin cancers. Furthermore, these adherent participants achieved a comparison–intervention difference that was closer to the trial goal (at year 1, 12.1%, and at year 6, 11.1%; ref. 30). Like many previous studies of diet and skin cancer, recorded dietary intake was dependent on self-report. Greater underreporting has been associated with higher BMI (47), but FFQ self-reported diet has been shown to correlate with nutritional biomarkers and chronic disease measures in some studies, but not all (30, 48). However, the validity of FFQ may be less critical given the randomized treatment assignment and large sample size. In addition, as the WHI DM Trial was designed to examine the effect of a low-fat dietary pattern on breast and colorectal cancer as well as cardiovascular disease, post hoc analyses of melanoma risk may lack statistical power to detect differences. Finally, this study was dependent upon self-report of NMSCs with no indication of type (e.g., basal cell or squamous cell carcinoma), but others have found self-report of skin cancer to be reliable (49, 50).

In conclusion, our results do not support a role for reducing dietary fat to prevent skin cancer in postmenopausal women. However, further investigations of lower fat diets in women who are consuming a baseline moderate-fat diet, or of larger dietary change, are relevant areas for future research in melanoma prevention.

Disclosure of Potential Conflicts of Interest

J.Y. Tang is a consultant/advisory board member of Genentech. The other authors disclosed no potential conflicts of interest.

Authors' Contributions

Conception and design: M. Stefanick, J.Y. Tang

Development of methodology: M. Stefanick, J.Y. Tang

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Stefanick, L. Van Horn, J.Y. Tang

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.S. Gamba, M. Stefanick, J. Larson, E. Linos, J.R. Marshall, J.Y. Tang

Writing, review, and/or revision of the manuscript: C.S. Gamba, M. Stefanick, J. Shikany, J. Larson, E. Linos, S.T. Sims, J.R. Marshall, L. Van Horn, N. Zeitouni, J.Y. Tang

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C.S. Gamba, J. Larson, J.Y. Tang

Study supervision: M. Stefanick, L. Van Horn, J.Y. Tang

Grant Support

This study was supported in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number 1K23AR056736-01) and the Damon Runyon Clinical Investigator Award (to J.Y. Tang). C.S. Gamba received a Stanford Medical Scholars Fellowship and Selected Professions Fellowship from the American Association of University Women. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts N01WH22110, 24152, 32100–2, 32105–6, 32108–9, 32111–13, 32115, 32118–32119, 32122, 42107–26, 42129–32, and 44221.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors thank the Program Office: Jacques Rossouw, Shari Ludlam, Joan McGowan, Leslie Ford, and Nancy Geller (National Heart, Lung, and Blood Institute, Bethesda, MD) Clinical Coordinating Center: Clinical Coordinating Center: Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg (Fred Hutchinson Cancer Research Center, Seattle, WA) Investigators and Academic Centers: JoAnn E. Manson (Brigham and Women's Hospital, Harvard Medical School, Boston, MA); Barbara V. Howard (MedStar Health Research Institute/Howard University, Washington, DC); Marcia L. Stefanick (Stanford Prevention Research Center, Stanford, CA); Rebecca Jackson (The Ohio State University, Columbus, OH); Cynthia A. Thomson (University of Arizona, Tucson/Phoenix, AZ); Jean Wactawski-Wende (University at Buffalo, Buffalo, NY); Marian Limacher (University of Florida, Gainesville/Jacksonville, FL); Robert Wallace (University of Iowa, Iowa City/Davenport, IA); Lewis Kuller (University of Pittsburgh, Pittsburgh, PA); and Sally Shumaker (Wake Forest University School of Medicine, Winston-Salem, NC).

  • Received April 1, 2013.
  • Revision received May 16, 2013.
  • Accepted May 16, 2013.
  • ©2013 American Association for Cancer Research.

References

  1. 1.↵
    1. Rogers HW,
    2. Weinstock MA,
    3. Harris AR,
    4. Hinckley MR,
    5. Feldman SR,
    6. Fleischer AB,
    7. et al.
    Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010;146:283–7.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Miller DL,
    2. Weinstock MA
    . Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994;30:774–8.
    OpenUrlCrossRefPubMed
  3. 3.↵
    American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
  4. 4.↵
    1. Epstein JH
    . Photocarcinogenesis, skin cancer, and aging. J Am Acad Dermatol 1983;9:487–502.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Rosso S,
    2. Zanetti R,
    3. Pippione M,
    4. Sancho-Garnier H
    . Parallel risk assessment of melanoma and basal cell carcinoma: skin characteristics and sun exposure. Melanoma Res 1998;8:573–83.
    OpenUrlPubMed
  6. 6.↵
    1. Rivers JK
    . Is there more than one road to melanoma? Lancet 2004;363:728–30.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Ziegler A,
    2. Jonason AS,
    3. Leffell DJ,
    4. Simon JA,
    5. Sharma HW,
    6. Kimmelman J,
    7. et al.
    Sunburn and p53 in the onset of skin cancer. Nature 1994;372:773–6.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Purdue MP,
    2. Freeman LE,
    3. Anderson WF,
    4. Tucker MA
    . Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol 2008;128:2905–8.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Linos E,
    2. Swetter SM,
    3. Cockburn MG,
    4. Colditz GA,
    5. Clarke CA
    . Increasing burden of melanoma in the United States. J Invest Dermatol 2009;129:1666–74.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Christenson LJ,
    2. Borrowman TA,
    3. Vachon CM,
    4. Tollefson MM,
    5. Otley CC,
    6. Weaver AL,
    7. et al.
    Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005;294:681–90.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Black HS,
    2. Thornby JI,
    3. Wolf JE Jr.,
    4. Goldberg LH,
    5. Herd JA,
    6. Rosen T,
    7. et al.
    Evidence that a low-fat diet reduces the occurrence of non-melanoma skin cancer. Int J Cancer 1995;62:165–9.
    OpenUrlPubMed
  12. 12.↵
    1. Ibiebele TI,
    2. van der Pols JC,
    3. Hughes MC,
    4. Marks GC,
    5. Green AC
    . Dietary fat intake and risk of skin cancer: a prospective study in Australian adults. Int J Cancer 2009;125:1678–84.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Ibiebele TI,
    2. van der Pols JC,
    3. Hughes MC,
    4. Marks GC,
    5. Williams GM,
    6. Green AC
    . Dietary pattern in association with squamous cell carcinoma of the skin: a prospective study. Am J Clin Nutr 2007;85:1401–8.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Hughes MC,
    2. van der Pols JC,
    3. Marks GC,
    4. Green AC
    . Food intake and risk of squamous cell carcinoma of the skin in a community: the Nambour skin cancer cohort study. Int J Cancer 2006;119:1953–60.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. van der Pols JC,
    2. Hughes MC,
    3. Ibiebele TI,
    4. Marks GC,
    5. Green AC
    . Food intake and risk of basal cell carcinoma in an 11-year prospective study of Australian adults. Eur J Clin Nutr 2011;65:39–46.
    OpenUrlPubMed
  16. 16.↵
    1. Hunter DJ,
    2. Colditz GA,
    3. Stampfer MJ,
    4. Rosner B,
    5. Willett WC,
    6. Speizer FE
    . Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women. Ann Epidemiol 1992;2:231–9.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Davies TW,
    2. Treasure FP,
    3. Welch AA,
    4. Day NE
    . Diet and basal cell skin cancer: results from the EPIC-Norfolk cohort. Br J Dermatol 2002;146:1017–22.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. van Dam RM,
    2. Huang Z,
    3. Giovannucci E,
    4. Rimm EB,
    5. Hunter DJ,
    6. Colditz GA,
    7. et al.
    Diet and basal cell carcinoma of the skin in a prospective cohort of men. Am J Clin Nutr 2000;71:135–41.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Veierod MB,
    2. Thelle DS,
    3. Laake P
    . Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer 1997;71:600–4.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Bain C,
    2. Green A,
    3. Siskind V,
    4. Alexander J,
    5. Harvey P
    . Diet and melanoma. An exploratory case-control study. Ann Epidemiol 1993;3:235–8.
    OpenUrlPubMed
  21. 21.↵
    1. Millen AE,
    2. Tucker MA,
    3. Hartge P,
    4. Halpern A,
    5. Elder DE,
    6. Guerry Dt,
    7. et al.
    Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004;13:1042–51.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Stryker WS,
    2. Stampfer MJ,
    3. Stein EA,
    4. Kaplan L,
    5. Louis TA,
    6. Sober A,
    7. et al.
    Diet, plasma levels of beta-carotene and alpha-tocopherol, and risk of malignant melanoma. Am J Epidemiol 1990;131:597–611.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Kirkpatrick CS,
    2. White E,
    3. Lee JA
    . Case-control study of malignant melanoma in Washington State. II. Diet, alcohol, and obesity. Am J Epidemiol 1994;139:869–80.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Le Marchand L,
    2. Saltzman BS,
    3. Hankin JH,
    4. Wilkens LR,
    5. Franke AA,
    6. Morris SJ,
    7. et al.
    Sun exposure, diet, and melanoma in Hawaii Caucasians. Am J Epidemiol 2006;164:232–45.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Djuric Z,
    2. Lewis SM,
    3. Lu MH,
    4. Mayhugh M,
    5. Tang N,
    6. Hart RW
    . Effect of varying dietary fat levels on rat growth and oxidative DNA damage. Nutr Cancer 2001;39:214–9.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Meeran SM,
    2. Singh T,
    3. Nagy TR,
    4. Katiyar SK
    . High-fat diet exacerbates inflammation and cell survival signals in the skin of ultraviolet B-irradiated C57BL/6 mice. Toxicol Appl Pharmacol 2009;241:303–10.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Black HS,
    2. Lenger WA,
    3. Gerguis J,
    4. Thornby JI
    . Relation of antioxidants and level of dietary lipid to epidermal lipid peroxidation and ultraviolet carcinogenesis. Cancer Res 1985;45:6254–9.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Erickson KL
    . Dietary fat influences on murine melanoma growth and lymphocyte-mediated cytotoxicity. J Natl Cancer Inst 1984;72:115–20.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Ritenbaugh C,
    2. Patterson RE,
    3. Chlebowski RT,
    4. Caan B,
    5. Fels-Tinker L,
    6. Howard B,
    7. et al.
    The women's health initiative dietary modification trial: overview and baseline characteristics of participants. Ann Epidemiol 2003;13:S87–S97.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Prentice RL,
    2. Caan B,
    3. Chlebowski RT,
    4. Patterson R,
    5. Kuller LH,
    6. Ockene JK,
    7. et al.
    Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:629–42.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Beresford SA,
    2. Johnson KC,
    3. Ritenbaugh C,
    4. Lasser NL,
    5. Snetselaar LG,
    6. Black HR,
    7. et al.
    Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:643–54.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Howard BV,
    2. Van Horn L,
    3. Hsia J,
    4. Manson JE,
    5. Stefanick ML,
    6. Wassertheil-Smoller S,
    7. et al.
    Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:655–66.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Hays J,
    2. Hunt JR,
    3. Hubbell FA,
    4. Anderson GL,
    5. Limacher M,
    6. Allen C,
    7. et al.
    The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13:S18–77.
    OpenUrlCrossRefPubMed
  34. 34.↵
    Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61–109.
    OpenUrlCrossRefPubMed
  35. 35.↵
    US Department of Health and Human Services. Nutrition and Your Health: Dietary Guidelines for Americans. 3rd ed. Washington, DC: US Department of Health and Human Services; 1990.
  36. 36.↵
    1. Patterson RE,
    2. Kristal AR,
    3. Tinker LF,
    4. Carter RA,
    5. Bolton MP,
    6. Agurs-Collins T
    . Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol 1999;9:178–87.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Prentice RL,
    2. Thomson CA,
    3. Caan B,
    4. Hubbell FA,
    5. Anderson GL,
    6. Beresford SA,
    7. et al.
    Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst 2007;99:1534–43.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Curb JD,
    2. McTiernan A,
    3. Heckbert SR,
    4. Kooperberg C,
    5. Stanford J,
    6. Nevitt M,
    7. et al.
    Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003;13:S122–8.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Rossouw JE,
    2. Anderson GL,
    3. Prentice RL,
    4. LaCroix AZ,
    5. Kooperberg C,
    6. Stefanick ML,
    7. et al.
    Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Anderson GL,
    2. Limacher M,
    3. Assaf AR,
    4. Bassford T,
    5. Beresford SA,
    6. Black H,
    7. et al.
    Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Jackson RD,
    2. LaCroix AZ,
    3. Gass M,
    4. Wallace RB,
    5. Robbins J,
    6. Lewis CE,
    7. et al.
    Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669–83.
    OpenUrlCrossRefPubMed
  42. 42.↵
    World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: WCRF/AICR; 2007.
  43. 43.↵
    1. Kushi LH,
    2. Byers T,
    3. Doyle C,
    4. Bandera EV,
    5. McCullough M,
    6. McTiernan A,
    7. et al.
    American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2006;56:254–81; quiz 313-4.
    OpenUrlCrossRefPubMed
  44. 44.↵
    Women's Health Initiative Study Group. Dietary adherence in the Women's Health Initiative Dietary Modification Trial. J Am Diet Assoc 2004;104:654–8.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Martin-Lopez R,
    2. Hernandez-Barrera V,
    3. De Andres AL,
    4. Garrido PC,
    5. De Miguel AG,
    6. Garcia RJ
    . Breast and cervical cancer screening in Spain and predictors of adherence. Eur J Cancer Prev 2010;19:239–45.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Saraiya M,
    2. Hall HI,
    3. Thompson T,
    4. Hartman A,
    5. Glanz K,
    6. Rimer B,
    7. et al.
    Skin cancer screening among U.S. adults from 1992, 1998, and 2000 National Health Interview Surveys. Prev Med 2004;39:308–14.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Neuhouser ML,
    2. Tinker L,
    3. Shaw PA,
    4. Schoeller D,
    5. Bingham SA,
    6. Horn LV,
    7. et al.
    Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol 2008;167:1247–59.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Willett W
    . Nutritional epidemiology. 2nd ed. New York, NY: Oxford University Press; 1998.
  49. 49.↵
    1. Ming ME,
    2. Levy RM,
    3. Hoffstad OJ,
    4. Filip J,
    5. Gimotty PA,
    6. Margolis DJ
    . Validity of patient self-reported history of skin cancer. Arch Dermatol 2004;140:730–5.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Colditz GA,
    2. Martin P,
    3. Stampfer MJ,
    4. Willett WC,
    5. Sampson L,
    6. Rosner B,
    7. et al.
    Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 1986;123:894–900.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 22 (9)
September 2013
Volume 22, Issue 9
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Low-Fat Diet and Skin Cancer Risk: The Women's Health Initiative Randomized Controlled Dietary Modification Trial
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Low-Fat Diet and Skin Cancer Risk: The Women's Health Initiative Randomized Controlled Dietary Modification Trial
Christina S. Gamba, Marcia L. Stefanick, James M. Shikany, Joseph Larson, Eleni Linos, Stacy T. Sims, James Marshall, Linda Van Horn, Nathalie Zeitouni and Jean Y. Tang
Cancer Epidemiol Biomarkers Prev September 1 2013 (22) (9) 1509-1519; DOI: 10.1158/1055-9965.EPI-13-0341

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Low-Fat Diet and Skin Cancer Risk: The Women's Health Initiative Randomized Controlled Dietary Modification Trial
Christina S. Gamba, Marcia L. Stefanick, James M. Shikany, Joseph Larson, Eleni Linos, Stacy T. Sims, James Marshall, Linda Van Horn, Nathalie Zeitouni and Jean Y. Tang
Cancer Epidemiol Biomarkers Prev September 1 2013 (22) (9) 1509-1519; DOI: 10.1158/1055-9965.EPI-13-0341
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement